Filing Flows › Regeneron Pharmaceuticals (REGN) › Net income
Regeneron Pharmaceuticals (REGN) net income by quarter
Regeneron Pharmaceuticals' net income was $1.9B in Q3 2026 (third quarter 2026), +50% from Q2 2026. Over the last 7 quarters it ranged from $727M (Q1 2026) to $1.9B (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.9B | +50% | +33% |
| Q2 2026 | $1.3B | +78% | -7% |
| Q1 2026 | $727M | -14% | -10% |
| Q4 2025 | $845M | -42% | — |
| Q3 2025 | $1.5B | +5% | — |
| Q2 2025 | $1.4B | +72% | — |
| Q1 2025 | $809M | — | — |
Q3 2026 at a glance
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is Regeneron Pharmaceuticals' net income?
Regeneron Pharmaceuticals' net income was $1.9B in Q3 2026 (third quarter 2026), +50% from Q2 2026.
How has Regeneron Pharmaceuticals' net income changed?
Over the last 7 quarters it ranged from $727M (Q1 2026) to $1.9B (Q3 2026).
Q3 2026 results → · How Regeneron Pharmaceuticals makes money →